# US 10,864,109 B2 · Method and system for reducing the likelihood of colorectal cancer in a human being > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 10,864,109 B2 - Document ID: US10864109B2 - Status: Granted - Kind: B2 - Application number: 16/776,861 - Filed: 2020-01-30 - Published: 2020-05-28 - Granted: 2020-12-15 - Earliest claimed: 2011-02-04 - Applicants: Joseph E. Kovarik - Inventors: Joseph E. Kovarik - Web page: https://patentgrep.com/patent/US10864109B2 ## CPC - A61F 5/566: {Intra-oral devices} - A61K 31/733: Fructosans, e.g. inulin - A61K 35/74: Bacteria (therapeutic use of a bacterial protein A61K38/00) - A61P 35/00: Antineoplastic agents - Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change - A61F: FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS (dental prosthetics A61C) - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS - Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE ## Abstract A system and method for reducing the likelihood of colorectal cancer in a human being includes the modification of an individual's gut microbes by employing a Clustered Regularly Interspaced Short Palindromic Repeats-CRISPR-associated system (CRISPR-Cas) or Clustered Regularly Interspaced Short Palindromic Repeats from Prevotella and Francisella 1 (CRISPR/Cpf1) system to modify only bacterial genes of bacteria that reside in the human gut that are non-homologous to those encompassed in the human genome, and in particular, to administer a therapeutically effective amount of a bacterial formulation comprising F. prausnitzii that has been modified to produce one of alliin or butyrate. ## Claims ### Claim 1 A method for reducing the likelihood of colorectal cancer in an individual human being, said method comprising: substantially reducing the human being's resident populations of gut microbes prior to administering a therapeutically effective amount of a bacterial formulation comprising Faecalibacterium prausnitzii; and providing inulin in an amount sufficient to reduce the pH in the colon of the human being to achieve acidifying of the colon and wherein said bacterial formulation further includes a microbe comprising Veillonella. ### Claim 2 (depends on 1) The method of claim 1, wherein the Faecalibacterium prausnitzii bacteria employed are isolated from a human being's stool. ### Claim 3 (depends on 1) The method of claim 1, wherein the Faecalibacterium prausnitzii bacteria employed are from the human being treated. ### Claim 4 (depends on 1) The method of claim 1, wherein the bacterial formulation comprises bacteria modified via a clustered regularly interspaced short pallindromic repeats (CRISPR) CRISPR associated protein (Cas) system to express p53. ### Claim 5 (depends on 1) The method of claim 1, further comprising reducing H. pylori populations in the individual human being. ### Claim 6 (depends on 1) The method of claim 1, wherein the colon is acidified to a degree that intestinal Mg.sup.2+ absorption by the human being is enhanced. ### Claim 7 (depends on 1) The method of claim 1, wherein the bacterial formulation further comprises a bacterium selected from the group consisting of comprising Chlamydia, Shigella flexneri, Mycoplasma, and H. pylori. ### Claim 8 (depends on 1) The method of claim 1, wherein the bacterial formulation further comprises Chlamydia bacterium. ### Claim 9 (depends on 1) The method of claim 1, wherein the bacterial formulation further comprises Shigella flexneri bacterium. ### Claim 10 (depends on 1) The method of claim 1, wherein the bacterial formulation further comprises Mycoplasma bacterium. ### Claim 11 (depends on 1) The method of claim 1, wherein the bacterial formulation further comprises H. pylori bacterium. ### Claim 12 (depends on 1) The method of claim 1, wherein said bacterial formulation further includes a microbe selected from the group consisting of Streptococcus and Treponema. ### Claim 13 A method for reducing the likelihood of colorectal cancer in an individual human being, said method comprising: substantially reducing the human being's resident populations of gut microbes prior to administering a therapeutically effective amount of a bacterial formulation comprising Faecalibacterium prausnitzii; and providing inulin in an amount sufficient to reduce the pH in the colon of the human being to achieve acidifying of the colon and wherein said bacterial formulation further includes a microbe comprising Streptococcus. ### Claim 14 (depends on 13) The method of claim 13, wherein said bacterial formulation further includes a microbe selected from the group consisting of Veillonella and Treponema. ### Claim 15 (depends on 13) The method of claim 13, wherein the bacterial formulation further comprises a bacterium selected from the group consisting of comprising Chlamydia, Shigella flexneri, Mycoplasma, and H. pylori. ### Claim 16 (depends on 13) The method of claim 13, wherein the bacterial formulation comprises bacteria modified via a clustered regularly interspaced short pallindromic repeats (CRISPR) CRISPR associated protein (Cas) system to express p53. ### Claim 17 A method for reducing the likelihood of colorectal cancer in an individual human being, said method comprising: substantially reducing the human being's resident populations of gut microbes prior to administering a therapeutically effective amount of a bacterial formulation comprising Faecalibacterium prausnitzii; and providing inulin in an amount sufficient to reduce the pH in the colon of the human being to achieve acidifying of the colon, and wherein said bacterial formulation further includes a microbe selected from the group consisting of Prevotella, H. pylori and Treponema, that has been modified by using a CRISPR-Cas or CRISPR-Cpf1 system to excise virulence factor genes. ### Claim 18 (depends on 17) The method of claim 17, wherein said bacterial formulation further includes a microbe selected from the group consisting of Streptococcus and Veillonella. ### Claim 19 (depends on 17) The method of claim 17, wherein the bacterial formulation comprises bacteria modified via a clustered regularly interspaced short pallindromic repeats (CRISPR) CRISPR associated protein (Cas) system to express p53. ### Claim 20 (depends on 17) The method of claim 17, wherein the bacterial formulation further comprises a bacterium selected from the group consisting of comprising Chlamydia, Shigella flexneri, Mycoplasma, and H. pylori.